...
【24h】

Physics aspects of setting up a multicenter clinical trial involving internal dosimetry of radioiodine reatment of differentiated thyroid cancer

机译:建立多中心临床试验的物理方面涉及涉及分化的甲状腺癌的放射性碘治疗内部剂量性的多中心临床试验

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The field of molecular radiotherapy is expanding rapidly, with the advent of many new radiotherapeutics for the treatment of common as well as for rare cancers. Treatment outcome is dependent on the absorbed doses delivered to target volumes and to healthy organs-at-risk, which are shown to vary widely from fixed administrations of activity. There have been significant developments in quantitative imaging and internal dosimetry hi recent years, although clinical implementation of these methods has been slow in comparison with external beam radiotherapy, partly due to there being relatively few patients treated at single centers. Multicenter clinical trials are therefore essential to acquire the data required to ensure best practice and to develop the personalized treatment planning that this area is well suited to, due to the unrivalled opportunity to image the therapeutic drug in vivo. Initial preparation for such trials requires a significant effort in terms of resources and trial design. Imaging systems in participating centers must be characterized and set up for quantitative imaging to allow for collation of data. Data transfer for centralized processing is usually necessary but is hindered hi some cases by data protection regulations and local logistics. Recent multicenter clinical trials involving radioiodine therapy have begun to establish the procedures necessary for quantitative SPECT imaging in a multicenter setting using standard and anthropomorphic phantoms. The establishment of national and international multicenter imaging and dosimetry networks will provide frameworks to develop and harmonize best practice with existing therapeutic procedures and to ensure rapid and optimized clinical implementation of new radiotherapeutics across all centers of excellence that offer molecular radiotherapy. This will promote networks and collaborations that can provide a sound basis for further developments and will ensure that nuclear medicine maintains a key role in future developments.
机译:分子放射治疗领域正在迅速扩张,随着许多新的放射治疗方法的出现,用于治疗常见以及罕见的癌症。治疗结果依赖于递送给靶体积的吸收剂量和健康的器官 - 风险,其显示出从固定的活性施用的广泛变化。定量成像和内部剂量近年来存在显着的发展,尽管与外梁放射治疗相比,这些方法的临床实施缓慢,部分原因是在单个中心治疗的患者相对较少。因此,多中心临床试验必须获取确保最佳实践所需的数据,并制定该领域非常适合的个性化待遇计划,因为无与伦比的体内成像治疗药物。此类试验的初步准备需要在资源和试验设计方面进行重大努力。必须表征参与中心的成像系统,并设置用于定量成像以允许数据排列。集中处理的数据传输通常是必需的,但在某些情况下通过数据保护规则和当地物流受到阻碍。最近涉及放射性碘治疗的多中心临床试验已经开始建立使用标准和拟人偶像的多中心设置中定量SPECT成像所需的程序。国家和国际多中心成像和剂量算法的建立将提供框架,以发展和协调现有治疗程序的最佳实践,并确保在所有卓越中心提供分子放射治疗的所有卓越中心的新放射治疗方法。这将促进可以为进一步发展提供合理基础的网络和合作,并将确保核检在未来的发展中保持关键作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号